LHDX - LHDX STOCK NEWS

Lucira Health, Inc. (LHDX) announced preliminary unaudited revenue results for Q4 and full year 2021, projecting Q4 revenue between $58 million and $60 million, a 300% growth over Q3 2021. Full-year revenue is estimated between $90 million and $92 million. The company anticipates exceeding $450 million in revenue for 2022, driven by strong demand for its at-home molecular tests. Despite the positive outlook, these preliminary figures are subject to audit and may change. Lucira aims to expand its COVID-19 testing business and introduce new products in 2022.

Lucira Health, Inc. (LHDX) has announced a distribution agreement to supply at least 600,000 COVID-19 test kits in 2022 through Co-Defend and Co-Protect. This partnership leverages Co-Defend's extensive network to make Lucira's at-home self-test, which provides PCR-quality results in 30 minutes, widely accessible. The test's efficacy has been confirmed in clinical trials, showcasing a 98% accuracy rate comparable to high-sensitivity tests. Lucira's technology can also detect all analyzed Omicron variant sequences, enhancing its market relevance amidst ongoing pandemic concerns.

Lucira Health (LHDX) has partnered with Switch Health Solutions to enhance access to at-home molecular COVID-19 tests as Omicron cases increase. Through this agreement, Lucira will supply over 2 million test kits in 2022. Their tests provide PCR-quality results in just 30 minutes. Recent confirmation shows that Lucira's kits can detect 100% of Omicron strain genomes analyzed. With Interim Order authorization from Health Canada, these self-test kits are now available for distribution in Canada, offering a reliable option for early infection detection.

Lucira Health, Inc. (Nasdaq: LHDX) announced that its COVID-19 Check-It and All-In-One test kits can detect 100% of genome sequences of the Omicron variant, as confirmed by evaluation against the GISAID database. These self-test kits provide PCR-quality results at home within 30 minutes and do not require a prescription or additional equipment. Lucira's tests are designed to remain effective amid viral mutations and have shown a 98% accuracy rate in clinical comparisons with high-sensitivity tests. This innovation aims to facilitate safer travel and gatherings during the pandemic.

Lucira Health, Inc. (LHDX) reported a record revenue of $15.0 million for Q3 2021, marking a 21% sequential growth. The company reopened online sales for its OTC COVID-19 Test Kit and received PSAR approval from Singapore's Health Sciences Authority. With a projected revenue of at least $30 million for Q4 and over $150 million for 2022, Lucira is consolidating manufacturing in the Dominican Republic due to labor shortages in Michigan. The GAAP net loss widened to $27.5 million from $11.8 million YoY, attributed to increased operating expenses.

Lucira Health (Nasdaq: LHDX) announced that its LUCIRA™ CHECK IT COVID-19 Test Kit is now available on Amazon in the U.S. This emergency use authorized self-test offers PCR-level accuracy, providing results in as little as 11 minutes. Users can access digital verification via the LUCI PASS™. In clinical trials, the test demonstrated a 98% accuracy rate compared to a leading molecular test. The kit is designed for independent use without medical supervision, aiming to enhance COVID-19 testing accessibility during the holiday season.

Lucira Health, a medical technology firm, will release its third quarter 2021 financial results on November 11, 2021. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, where management will discuss financial results and provide corporate updates. Lucira specializes in innovative infectious disease test kits, offering PCR-quality testing through user-friendly, palm-sized kits that provide accurate COVID-19 results in under 30 minutes. The LUCIRA CHECK IT and All-In-One Test Kits feature SMS verification, catering to travel and work testing requirements.

Lucira Health (Nasdaq: LHDX) has announced the availability of its LUCIRA™ CHECK IT COVID-19 Test Kit for online purchase, following FDA Emergency Use Authorization. The at-home, single-use test delivers PCR-quality results in under 30 minutes and costs $75. It is designed for easy self-administration without the need for a prescription or additional equipment. Clinical trials indicate a 98% accuracy rate compared to high-sensitivity tests. The test provides rapid results, with positive results in as little as 11 minutes, and offers a digital LUCI PASS™ result for work and travel verification.

Lucira Health (Nasdaq: LHDX) has received approval from Singapore's Health Sciences Authority for its LUCIRA CHECK IT COVID-19 Test Kit via the Pandemic Special Access Route. This kit delivers lab-quality molecular results in just 30 minutes. The partnership with Labgistics Asia Pte Ltd facilitates the kit's importation and distribution in Singapore, enhancing Lucira's international expansion efforts. Notably, it is the only self-test in Singapore using gold standard molecular technology, further solidifying its role in the country's COVID-19 testing strategy.